Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
The proposed research will determine the effectiveness of blocking aldosterone for improving
the health and function of arteries in patients with autosomal dominant polycystic kidney
disease (ADPKD). The study also will provide insight into how blocking aldosterone improves
artery health by determining the physiological mechanisms (biological reasons) involved.
Overall, the proposed research will provide important new scientific evidence upon which
physicians can base recommendations to patients with ADPKD to decrease risk of developing
cardiovascular diseases.
Phase:
Phase 3
Details
Lead Sponsor:
University of Colorado, Denver
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)